Legend Biotech stock steadies as short interest stays elevated

Published on 09/20/2026 at 18:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Legend Biotech stock closed at USD 17.61 on September 18, 2026 on Nasdaq, with 8.50 percent of its float sold short as of August 31, 2026. The biotech’s high short interest underscores ongoing investor caution ahead of its next data and earnings catalysts.

LEGN, US52490G1022, Illustration mit AI erstellt.

Legend Biotech Corp. stock (ISIN US52490G1022) last closed at USD 17.61 on Nasdaq on September 18, 2026, with a modest gain of 0.17% versus the prior session, while short sellers continued to hold a sizeable position in the name as of August 31, 2026.

Short interest remains a key factor

According to MarketBeat on September 18, 2026, Legend Biotech had 16.48 million shares sold short as of August 31, 2026, representing 8.50% of the public float. This level of short interest is substantial and signals that a notable portion of the market is positioning for downside or hedging exposure in the stock as of late summer 2026.

The same overview from MarketBeat shows Legend Biotech’s shares closing at USD 17.61 on Nasdaq on September 18, 2026, up USD 0.03 or 0.17% on the day. With an extended-hours indication of USD 17.73 on the same date, the intraday move remained relatively muted, but the combination of a mid-teens share price and an 8.50% short-interest share of float gives investors a concrete sense of how contested the stock currently is.

Fundamental backdrop and recent leadership change

The elevated short positioning comes against the backdrop of Legend Biotech’s ongoing efforts to build a broader commercial oncology portfolio, including its role in cell therapies, and a recent leadership transition that underscores the company’s growth ambitions. As OncoDaily reported on September 20, 2026, executive Ingrid Zhang described her first week at Legend Biotech as extremely welcoming and highlighted her excitement to advance the company’s mission to transform patient outcomes. While the short-interest data reflects skepticism in the market, management commentary aims to reinforce the long-term clinical and commercial trajectory.

Investors typically weigh such qualitative signals alongside hard numbers from recent earnings reports. For Legend Biotech, the most recent quarterly and annual fundamentals remain central to judging whether the current share price near USD 17.61 and the 8.50% short-interest ratio appropriately reflect the risk-reward profile. The short-interest statistics as of August 31, 2026, provide a clear, dated snapshot of market positioning, while management’s emphasis on mission and pipeline development suggests that upcoming data readouts and potential regulatory milestones will be crucial in shifting sentiment one way or the other.

Stock price level and investor perspective

Per the Nasdaq-referenced data summarized by MarketBeat, Legend Biotech stock’s closing price of USD 17.61 on September 18, 2026 on Nasdaq defines the current reference level for investors assessing entry or exit decisions. With the shares moving only 0.17% on that trading day despite the relatively high 8.50% short-interest share of float as of August 31, 2026, the market appears to be in a wait-and-see mode, balancing the potential for positive clinical and commercial surprises against the risk highlighted by short sellers.